» Articles » PMID: 35734074

Quality of Life After Intratympanic Steroid Injection for Ménière's Disease

Overview
Publisher Wiley
Date 2022 Jun 23
PMID 35734074
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study explores how treatment with intratympanic steroid injection affects quality of life, as well as several subjective complaints in patients with Ménière's disease.

Methods: Patients filled in the Ménière's Disease Outcome Questionnaire (MDOQ) and answered questions about subjective complaints. Scores before and after treatment were compared using paired tests.

Results: Forty-nine patients treated with intratympanic steroid injection were included. Quality of life was improved in 36 (73%) patients, the same in 9 (18%) patients, and lower in 4 (8%) patients. Overall, the mean change in MDOQ was +20.6 points (95% confidence interval +14.5 to +26.7 points,  < 0.001). The improvement was seen in the emotional, physical, and mental domain. Most patients experienced less vertigo and instability but did not notice change in subjective hearing, tinnitus, or aural fullness after treatment.

Conclusion: Treatment with intratympanic steroid injection leads to an improvement in quality of life in most patients. Moreover, the procedure is only minimally invasive. Based on the findings in this study, treatment with ITS should be discussed with every patient suffering from vertigo attacks due to active Ménière's disease.

Level Of Evidence: Level 4.

Citing Articles

Vestibular Drop Attack: An Analysis of the Therapeutic Response.

Carmona S, Fernandez M, Espona C Audiol Res. 2024; 14(1):27-34.

PMID: 38247560 PMC: 10801597. DOI: 10.3390/audiolres14010004.


Quality of life after intratympanic steroid injection for Ménière's disease.

Schenck A, Bommelje C, van Benthem P, Blom H Laryngoscope Investig Otolaryngol. 2022; 7(3):825-831.

PMID: 35734074 PMC: 9194969. DOI: 10.1002/lio2.798.

References
1.
Liu Y, Chi F, Yang T, Liu T . Assessment of complications due to intratympanic injections. World J Otorhinolaryngol Head Neck Surg. 2017; 2(1):13-16. PMC: 5698530. DOI: 10.1016/j.wjorl.2015.11.001. View

2.
Weckel A, Marx M, Esteve-Fraysse M . Control of vertigo in Ménière's disease by intratympanic dexamethasone. Eur Ann Otorhinolaryngol Head Neck Dis. 2017; 135(1):7-10. DOI: 10.1016/j.anorl.2017.07.002. View

3.
Schenck A, Bommelje C, van Benthem P, Blom H . Quality of life after intratympanic steroid injection for Ménière's disease. Laryngoscope Investig Otolaryngol. 2022; 7(3):825-831. PMC: 9194969. DOI: 10.1002/lio2.798. View

4.
Kato B, LaRouere M, Bojrab D, Michaelides E . Evaluating quality of life after endolymphatic sac surgery: The Ménière's Disease Outcomes Questionnaire. Otol Neurotol. 2004; 25(3):339-44. DOI: 10.1097/00129492-200405000-00023. View

5.
Perez-Garrigues H, Lopez-Escamez J, Perez P, Sanz R, Orts M, Marco J . Time course of episodes of definitive vertigo in Meniere's disease. Arch Otolaryngol Head Neck Surg. 2008; 134(11):1149-54. DOI: 10.1001/archotol.134.11.1149. View